Acquisition by Matthew Foehr of 240000 shares of OmniAb at 4.416 subject to Rule 16b-3
OABI Stock | USD 3.90 0.12 3.17% |
Under 63% of all OmniAb's traders are looking to take a long position. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that some traders are interested. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
Filed transaction by OmniAb Inc Director, Officer: President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
OmniAb's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the OmniAb's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
OmniAb Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
OmniAb is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
IPSC | Century Therapeutics | 20.74 | ||||
ACET | Adicet Bio | 15.63 | ||||
PASG | Passage Bio | 11.94 | ||||
GLUE | Monte Rosa | 5.93 | ||||
ERAS | Erasca | 5.04 | ||||
BCAB | Bioatla | 4.46 | ||||
ITOS | Iteos Therapeutics | 4.27 | ||||
OLMA | Olema Pharmaceuticals | 4.12 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
KROS | Keros Therapeutics | 2.02 | ||||
LEGN | Legend Biotech | 1.29 | ||||
IDYA | Ideaya Biosciences | 0.78 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
VRNA | Verona Pharma | 0.15 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
VOR | Vor Biopharma | 1.25 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |